Search results

1

Carrier-state of D allele in ACE gene insertion/deletion polymorphism is associated with coronary artery disease, in contrast to the C677→T transition in the MTHFR gene.

100%

Żak I., Niemiec P., Sarecka B., Balcerzyk A., Ciemniewski Z., Rudowska E., Dyląg S.

Acta Biochimica Polonica

|

2003

|

vol. 50

|

issue 2

527-534

EN

Angiotensin I-converting enzyme (ACE), which plays an important role in blood pressure regulation, and methylenetetrahydrofolate reductase (MTHFR) involved in homocysteine metabolism belong to a large group of polypeptides which may be potential risk factors for atherosclerosis and coronary artery disease (CAD). To assess whether polymorphisms of the genes encoding these peptides are associated with CAD in Silesian we conducted a study among 68 individuals suffering from CAD (including 52 cases after myocardial infarction), 51 subjects with positive family history of CAD and 111 controls. We analysed the distribution of genotypes and allele frequencies of the insertion/deletion (I/D) polymorphism in the ACE gene using PCR amplification, and the C677→T polymorphism in the MTHFR gene using PCR-RFLP analysis. We found that D allele frequency was significantly higher in CAD patients (61%) than in controls (43%) (P = 0.001, OR = 2.06). The D allele carriers (DD + ID genotypes) were more frequent in the CAD patients (85%) compared to control group (65%) (P = 0.003, OR = 3.14), whereas the familial CAD risk group shows the highest frequency of the ID genotype (57% vs 43% in controls). In contrast, the MTHFR polymorphism does not seem to be associated with the disease. Our data indicate that in Silesian CAD patients the disease is strongly associated with carrier-state of the ACE D allele, but not with the C677→T transition in the MTHFR gene.

2

Evaluation of the Results of Surgical Treatment in Ischaemic Mitral Regurgitation

100%

Wojtasik-Anioł M., Adamek-Kośmider A., Wojtasik L., Jaszewski R.

Polish Journal of Surgery

|

2008

|

vol. 80

|

issue 4

209-216

EN

The aim of the study was to assess the results of mitral valve surgery in patients with chronic coronary artery disease, subjected to concomitant coronary artery by-pass grafting (CABG).Material and methods. The study group comprised 24 patients (aged 48-72) with coronary artery disease and significant ischemic mitral regurgitation, who qualified for mitral annuloplasty concomitant with CABG. All patients underwent a review of medical history, NYHA and CCS class evaluation, electrocardiography, transthoracic echocardiography and coronarography. Patients were subjected to intra-operative transesophageal echocardiography; in the early postoperative period their clinical state was assessed and electrocardiography and transthoracic echocardiography were performed. The followup, 6-12 months after the surgery, included history of life comfort, NYHA and CCS class evaluation, electrocardiography and transthoracic echocardiography. Echocardiographic parameters were analyzed using Student's t-test and the STATISTICA 7.1 program.Results. Most patients were qualified into NYHA classes I and II postoperatively, as compared to class II, III or IV before the surgery. According to CCS class, 16 patients were asymptomatic and four were class I. Based on NYHA and CCS classes, patient life comfort was assessed before and after the surgery. Life comfort was improved in 20 patients. An improvement was achieved in all studied echocardiographic parameters, left ventricular ejection fraction, left ventricular end-systolic and diastolic diameters, left atrial diameter, vena contracta, effective regurgitant orifice, regurgitant volume, proximal isovelocity surface area, and regurgitant jet area. Pre- and postoperative mitral regurgitation grades were assessed: 13 patients had grade IV, eight had grade III and three had grade II mitral regurgitation prior to surgery, as compared to trace or grade I in 22 patients after surgery, and grade II in one patient following peri-operative myocardial infarction.Conclusions. Mitral annuloplasty concomitant with CABG significantly improved hemodynamic heart parameters, particularly left ventricular systolic function and ejection fraction, decreased left ventricular and left atrial dimensions, significantly reduced MR grades and improved patient life comfort.

3

Elevated high sensitivity C-reactive protein and uric acid levels in coronary artery ectasia

100%

Demir Ş., Karakoyun G., Kanadasi M.

Acta Biochimica Polonica

|

2014

|

vol. 61

|

issue 4

687-691

EN

Aim: The aim of this study is to examine uric asid (UA) and high sensitive C-Reactive protein (Hs-CRP) levels in patients with coronary artery ectasia (CAE). Materials and Methods: Ninety-eight patients with isolated CAE (mean age 57.5±10.3), (group-I), 110 patients with CAD but without CAE (mean age 56.3±10.7), (group-II), and 105 patients with normal coronary angiographies (mean age 58.1±10.8), (group-III) were included in the study. Blood samples of all individual were taken after coronary angiography from an antecubital vein, the patients uric acid and Hs-CRP levels were assessed. The severity of ectasia was evaluated and categorized according to Markis. Results: A significant difference was not seen in serum uric acid and Hs-CRP levels between CAE and CAD groups. However, relative to the control group, uric acid and Hs-CRP levels in CAE and CAD groups were higher to a significant degree (p=0.001, p<0.001, respectively), (p<0.001, p<0.001, respectively). The statistical significant was detected between subgroups type I and type IV, Hs-CRP and UA were statistically high in subgroup type I. (p=0.012, p=0.033, respectively) In multiple regression analysis, CAE and CAD were independently associated with UA (β=0.76; p<0.001, β=0.68; p<0.001, respectively) and Hs-CRP (β=0.66; p<0.01, β=0.62; p<0.01, respectively) along with diabetes mellitus (β=0.61; p=0.039, β=0.94; p=0.028, respectively). Conclusion: In conclusion, the blood uric acid and Hs-CRP values in our study have been observed to be higher in the individuals with coronary arteri ectasia in comparison to normal individuals, and the increase in these values were found to be parallel to the extent of the ectasia.

4

Coronary Artery Diagnosis Aided by Neural Network

88%

Stefko K.

Polish Journal of Medical Physics And Engineering

|

2007

|

vol. 13

|

issue 3

149-155

EN

Coronary artery disease is due to atheromatous narrowing and subsequent occlusion of the coronary vessel. Application of optimised feed forward multi-layer back propagation neural network (MLBP) for detection of narrowing in coronary artery vessels is presented in this paper. The research was performed using 580 data records from traditional ECG exercise test confirmed by coronary arteriography results. Each record of training database included description of the state of a patient providing input data for the neural network. Level and slope of ST segment of a 12 lead ECG signal recorded at rest and after effort (48 floating point values) was the main component of input data for neural network was. Coronary arteriography results (verified the existence or absence of more than 50% stenosis of the particular coronary vessels) were used as a correct neural network training output pattern. More than 96% of cases were correctly recognised by especially optimised and a thoroughly verified neural network. Leave one out method was used for neural network verification so 580 data records could be used for training as well as for verification of neural network.

5

Effects of Interval Training in Patients with Coronary Artery Disease and Positive Exercise Stress Test: A Pilot Study / Ocena Efektówtreningu Interwałowego u Pacjentów z Chorobą Niedokrwienną Serca i Dodatnią Próbą Wysiłkową

88%

Korzeniowska-Kubacka I., Dobraszkiewicz-Wasilewska B., Bilińska M., Rydzewska E., Rudnicki S., Piotrowicz R.

Advances in Rehabilitation

|

2011

|

vol. 25

|

issue 2

37-41

EN

Wstęp. Dodatnia próba wysiłkowa u pacjentów ze stabilną chorobą wieńcową nie stanowi przeciwwskazań do treningu fizycznego. Jednak w piśmiennictwie jest niewiele prac oryginalnych dotyczących efektów i bezpieczeństwa takiego treningu. Cel pracy. Celem pracy była ocena efektów i bezpieczeństwa treningu fizycznego u pacjentów ze stabilną chorobą wieńcową i dodatnią próbą wysiłkową. Metody. Badaniami objęto 30 pacjentów (mężczyźni, wiek 55±10 lat) po zawale serca i/lub operacyjnym leczeniu choroby wieńcowej z dodatnią próbą wysiłkową. Wszyscy badani uczestniczyli w 3 miesięcznym programie treningowym, który zawierał 2 cykle po 16 treningów interwałowych na cykloergometrze 3 razy w tygodniu. Na wstępie i po zakończeniu cyklu treningów wykonywano ergospirometryczną próbę wysiłkową (EPW). Limit tętna treningowego wyznaczono do częstotliwości rytmu serca o 10 uderzeń/min mniejszy od tej, przy której pojawiało się obniżenie odcinka ST o lmmwe wstępnej próbie wysiłkowej. Oce- nie poddano: czas trwania próby (minuty), czas do obniżenia odcinka ST o lmm (minuty), DP do obniżenia odcinka ST o lmm(mmHg/min), maxV02 (ml/kg/min), przebytą drogę (metry), maksymalne obciążenie (MEJ) oraz powikłania w czasie treningu. Wyniki. Po odbyciu programu treningowego nastąpiło istotne wydłużenie czasu próby z 11, 1±2 do 12.7±2.1 (p<0.001). wydłużenie czasu do obniżenia ST o limn z 10.2±2.3 do 11.8±2.3 (p=0.001). wzrost DPprzy obniżeniu ST o lmm z 186,5 51,3 do 208±48,6 (p<0.03). wzrost maxV02 z 21.4±4.6 do 24.6±5,1 (p<0.001), przebytej drogi z 565,6±142.6 do 686.1 150.5 (p<0.001) i maksymalnego obciążenia z 6.35±1.6 do 7.49±1.5 (p=0.002).Nie stwierdzono żadnych powikłań w czasie trwania treningów. Wnioski. Trening interwałowy poniżej progu niedokrwienia jest efektywny i bezpieczny u pacjentów ze stabilną chorobą wieńcową i dodatnią prób|ą wysiłkową.

6

Znaczenie czynników genetycznych w chorobie niedokrwiennej serca

75%

Gołąbek K., Strzelczyk J. K., Wiczkowski A.

Annales Academiae Medicae Silesiensis

|

2013

|

vol. 67

|

issue 1

33-39

EN

Coronary artery disease is multifactorial. In recent times due to the development of modern molecular biology techniques, candidate gene polymorphisms related to lipid metabolism the renin–angiotensin–aldosterone system and the regulation of coagulation and fibrinolysis as well as inflammatory response, have become a research topic. This article provides an overview of the most frequently studied polymorphisms.

PL

Choroba niedokrwienna serca ma charakter wieloczynnikowy. W ostatnim czasie ze względu na rozwój technik z zakresu biologii molekularnej tematem badań stały się polimorfizmy genów kandydatów, związanych m.in. z metabolizmem lipidów, z układem renina–angiotesyna–aldosteron (RAA), regulacją krzepnięcia i fibrynolizy oraz reakcją zapalną. W pracy przedstawiono przegląd wyników najczęściej badanych polimorfizmów.

7

Predicting heart attack in a patient post-radiation therapy using plaque CCTA analysis and serum biomarker test. Case report

75%

Tariq H., Amin S., Singh M., Morales-Pabon C. A., Cahill K. V., Harrison E. E.

OncoReview

|

2014

|

vol. 4

|

issue 2

A54-61

EN

Accelerated coronary artery disease (CAD) is a long term manifestation of chest irradiation that may progress to acute myocardial infarction (MI). We report the use of an algorithm-based biomarker test and coronary computed tomography angiography (CCTA) to identify accelerated CAD in a patient treated with chest irradiation and combination chemotherapy for non-Hodgkin’s lymphoma (NHL). Using a seven protein biomarker test with four incorporated clinical factors, we identified the patient had a 6 fold higher risk for future MI than expected for individuals at his age. Using CCTA, we characterized his plaques based on the following parameters: percent diameter stenosis (ranging from 30–70), percent area stenosis, percent necrotic core (NC), percent fibrotic core (FC), percent calcium core (CC), FC thickness, percent vessel wall to lumen, and NC to FC ratio. We identified a plaque in his left circumflex (LCX) with moderate percent diameter stenosis, high percent NC, low percent FC, absent FC thickness, high percent vessel wall to lumen ratio, and high NC to FC ratio as the most vulnerable to rupture and cause MI. The patient was educated about his risk of a future MI and started on maximum medical therapy. Nevertheless, he experienced a ST elevation MI (STEMI) in 185 days with occlusion at the vulnerable plaque site of his LCX. The recognition of a vulnerable plaque in a vulnerable patient may necessitate prophylactic stenting in vessels without severe obstruction. The serum biomarker test and CCTA plaque analysis may detect these patients in need of aggressive therapy.

8

Intensyfikacja leczenia farmakologicznego u pacjenta z dławicą i zaawansowaną chorobą wieńcową (bez opcji rewaskularyzacyjnej)

63%

Balsam P.

Pediatria i Medycyna Rodzinna

|

2013

|

vol. 9

|

issue 2

201-204

EN

In the last decades, the introduction of statins, benefits of angiotensin-converting enzyme inhibitors, coronary artery revascularisation or prophylactic programmes brought about the breakthrough in treating diseases of the circulatory system, in particular ischaemic heart disease. The basis for treating stable coronary artery disease is the administrations of drugs, such as: antiplatelet drugs, statins and angiotensin-converting enzyme inhibitors (particularly in concomitant indications) as medicines the improve survival as well as symptomatic drugs, particularly beta blockers, which may additionally influence the prognosis of patients with the history of heart attack. On the other hand, symptomatic patients with advanced coronary artery disease in whom revascularisation is not possible or burdened with too great risk and patients who do not consent to the procedure constitute a major therapeutic challenge for attending physicians. In such situations, additional options are worth considering, such as the application of metabolic drugs which are described in the standards as drugs added to the therapy conducted so far or used as substitutes in case of intolerance of current treatment. The management of the patient with coronary artery disease presented in this paper constitutes an example that pictures a difficult case of coronary artery disease treatment and a situation in which metabolic drugs are used.

PL

Wprowadzenie do leczenia statyn, korzyści ze stosowania inhibitorów konwertazy angiotensyny, rewaskularyzacja wieńcowa czy programy profilaktyczne doprowadziły w ostatnich dekadach do przełomu w zakresie leczenia schorzeń układu sercowo-naczyniowego, szczególnie w leczeniu choroby niedokrwiennej serca. Podstawę leczenia stabilnej choroby wieńcowej stanowi stosowanie leków: przeciwpłytkowego, statyny, inhibitora konwertazy angiotensyny (szczególnie w przypadku wskazań współistniejących) jako leków poprawiających przeżycie oraz leków objawowych, szczególnie beta-adrenolityków, które u pacjentów po zawale serca także mają wpływ na ich rokowanie. Z drugiej strony objawowi pacjenci z zawansowaną chorobą wieńcową bez opcji rewaskularyzacji lub bardzo wysokiego ryzyka zabiegu, osoby niewyrażające zgody na zabieg są dużym wyzwaniem terapeutycznym dla prowadzących lekarzy. W takich sytuacjach warto rozważyć dodatkowe opcje, na przykład zastosowanie leków metabolicznych, które są opisane w standardach jako leki dołączane do dotychczasowej terapii lub użyte jako zamiennik, w razie gdyby dotychczas stosowane leczenie było źle tolerowane. Opisane w artykule postępowanie z pacjentem z chorobą wieńcową jest przykładem, który obrazuje trudny przypadek terapii choroby wieńcowej oraz miejsce na zastosowanie leków metabolicznych.

9

Carrier-state of the A allele of – 455G>A polymorphism within the beta fibrinogen gene increases the risk of coronary artery disease in the presence of elevated concentration of serum triacylglycerols

63%

Sarecka-Hujar B., Zak I., Krauze J.

Annales Academiae Medicae Silesiensis

|

2009

|

vol. 63

|

issue 5

41-49

EN

BACKGROUND Fibrinogen promotes development of atherosclerosis by directed integration in atherosclerotic lesions where it is converted into fi brin. The aim of the study was to assess a relationship between –455G>A polymorphism of beta fi brinogen (FGB) gene and coronary artery disease (CAD) in the Polish patients from Upper Silesia region and to establish whether there are any interactions between this polymorphism and traditional risk factors that infl uence the risk of CAD. METHODS We analyzed 191 patients with angiographically documented CAD and 203 blood donors. Genetic analysis was performed using PCR-RFLP method. RESULTS The frequency of FGB -455G>A genotypes was compatible with Hardy- Weinberg equilibrium. There was no signifi cant diff erences in the distribution of A allele and A allele carriers of FGB polymorphism between cases and controls. We observed a tendency to higher level of plasma fibrinogen in subjects with AA or GA genotypes than in GG homozygotes. We also found strong synergistic eff ects between A allele carrier-state and increased level of triacylglycerols (TG) in determining the risk of CAD (SI=5.97, SIM=2.63). Carriers of A allele with elevated level of TG were 3-fold more frequent among cases than in control group (12.0% vs 3.9%, p=0.003,OR=3.34). CONCLUSIONS There is a synergistic eff ect between –455G>A polymorphism of FGB gene and elevated concentration of serum triacylglycerols which determine the risk of CAD.

PL

WSTĘP Fibrynogen promuje rozwój zmian miażdżycowych przez przyleganie do zmienionej ściany tętnic gdzie jest przekształcany w fibrynę. Celem niniejszej pracy była ocena związku między polimorfi zmem –455G>A genu kodującego łańcuch beta fibrynogenu (FGB) a ryzykiem choroby wieńcowej (CAD, ang. coronary artery disease) w grupie pacjentów z Górnego Śląska i ustalenie czy istnieją interakcje między tym polimorfi zmem a tradycyjnymi czynnikami ryzyka miażdżycy w determinowaniu ryzyka CAD. MATERIAŁ I METODY Grupę badaną stanowiło: 191 pacjentów z potwierdzoną koronarografi cznie CAD oraz 203 krwiodawców bez obciążeń chorobami sercowo-naczyniowymi. Polimorfi zm –455G>A genu FGB genotypowano metodą RFLP-PCR. Wyniki. Częstości genotypów polimorfi zmu -455G>A genu FGB były zgodne z równowagą Hardy-Weinberg’a. Nie stwierdzono znamiennych różnic w częstości allela A i nosicieli allela A polimorfi zmu genu FGB między pacjentami a grupą kontrolną. Obserwowano tendencję do występowania wyższego poziomu fi brynogenu w osoczu osób z genotypami AA i GA w porównaniu do poziomu fibrynogenu w osoczu osób z genotypem GG. Stwierdzono również silny synergiczny efekt między nosicielstwem allela A a podwyższonym poziomem triglicerydów w determinowaniu ryzyka CAD (indeksy synergii SI=5.97, SIM=2.63). Nosiciele allela A charakteryzujący się podwyższonym poziomem triglicerydów występowali trzykrotnie częściej w grupie chorych niż w kontroli (12.0% vs 3.9%, p=0.003,OR=3.34). WNIOSKI Przedstawione wyniki wskazują na synergiczny związek nosicielstwa allela A polimorfi zmu – 455G>A genu FGB z ponadnormatywnym stężeniem triglicerydów w surowicy krwi w kształtowaniu ryzyka CAD w populacji pacjentów z Górnego Śląska.

Refine search results

Carrier-state of D allele in ACE gene insertion/deletion polymorphism is associated with coronary artery disease, in contrast to the C677→T transition in the MTHFR gene.

Evaluation of the Results of Surgical Treatment in Ischaemic Mitral Regurgitation

Elevated high sensitivity C-reactive protein and uric acid levels in coronary artery ectasia

Coronary Artery Diagnosis Aided by Neural Network

Effects of Interval Training in Patients with Coronary Artery Disease and Positive Exercise Stress Test: A Pilot Study / Ocena Efektówtreningu Interwałowego u Pacjentów z Chorobą Niedokrwienną Serca i Dodatnią Próbą Wysiłkową

Znaczenie czynników genetycznych w chorobie niedokrwiennej serca

Predicting heart attack in a patient post-radiation therapy using plaque CCTA analysis and serum biomarker test. Case report

Intensyfikacja leczenia farmakologicznego u pacjenta z dławicą i zaawansowaną chorobą wieńcową (bez opcji rewaskularyzacyjnej)

Carrier-state of the A allele of – 455G>A polymorphism within the beta fibrinogen gene increases the risk of coronary artery disease in the presence of elevated concentration of serum triacylglycerols